G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
G1 Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 28, 2021
G1 Therapeutics reported fiscal year 2020 executive compensation information on April 28, 2021.
In 2020, six executives at G1 Therapeutics received on average a compensation package of $2M, a 19% decrease compared to previous year.
Average pay of disclosed executives at G1 Therapeutics
Mark A. Velleca, Chief Executive Officer, received $4M in total, which is about the same as previous year. 77% of Velleca's compensation, or $3.1M, was in option awards. Velleca also received $305K in non-equity incentive plan, $608K in salary, as well as $8.6K in other compensation.
Soma Gupta, Chief Commercial Officer, received a compensation package of $2.7M. 81% of the compensation package, or $2.2M, was in option awards.
Jennifer K. Moses, Chief Financial Officer, earned $1.7M in 2020, a 18% increase compared to previous year.
Mark Avagliano, Chief Business Officer, received $1.4M in 2020, which decreases by 74% compared to 2019.
Rajesh K. Malik, Chief Medical Officer, earned $1.4M in 2020, a 2% increase compared to previous year.
John E. Bailey, Jr, Chief Executive Officer, received $758K in 2020.
Related executives
John Bailey
G1 Therapeutics
Chief Executive Officer
Mark Velleca
G1 Therapeutics
Chief Executive Officer
Jennifer Moses
G1 Therapeutics
Chief Financial Officer
Mark Avagliano
G1 Therapeutics
Chief Business Officer
Rajesh Malik
G1 Therapeutics
Chief Medical Officer
Soma Gupta
G1 Therapeutics
Chief Commercial Officer
You may also like
Source: SEC filing on April 28, 2021.